Advanced Therapy Medicinal Products
Proteios is developing an innovative approach that empowers an organization’s discovery and manufacturing of Advanced Therapy Medicinal Products (ATMPs). Some of the anticipated advantages of ATMPs include: highly personalized therapy, direct application through infusion, longer lasting effect, address complex diseases, and improving health-related quality of life. Complex manufacturing and compliance with GMP standards has been a major challenge for the progress of ATMPs. The Proteios Chimera Platform is enabling: 1) new discoveries in Preclinical Research to better understand disease at the molecular level, 2) the cost-effective manufacturing of Biopharmaceuticals, Cell Therapies, Gene Therapies, and Antibody Therapeutics, 3) and the development of novel molecular diagnostics.